Not provided
Not provided
Not provided
Not provided
Not provided
Low enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Otsuka Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Brexpiprazole | Experimental | Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brexpiprazole | Drug | Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Phase B baseline to Phase B Week 6 in functional magnetic resonance imaging (fMRI) BOLD activation score in the ventromedial prefrontal cortex and amygdala, scanned by fMRI during performance of the Emotion-induction Task | Week 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Phase B baseline to Phase B Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score | Week 6 | |
| Change from Phase B baseline to Phase B Week 6 in Spielberger State Trait Anger Expression Inventory (STAXI-2) Part 1 | Week 6 |
Not provided
Inclusion Criteria:
Are 18 to 55 years of age, inclusive, at the time of informed consent with a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR™) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation
Have received a single, trial-approved SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening
Have a treatment history of inadequate ADT response to at least one ADT (but not > 3) for the current episode. The current major depressive episode must be ≥ 6 weeks in duration. (An inadequate ADT response is defined as < 50% reduction in depressive symptom severity, as measured by subject self-report on the MGH-ATRQ.)
To be eligible for this trial
Are right-handed (defined according to the Edinburgh Handedness Inventory) and have normal hearing and normal/corrected-to-normal vision
Are willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period
Eligibility confirmed through a telephone SAFER interview with the subject and an independent expert centralized rater
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Junichi Hashimoto, PhD | Otsuka Pharmaceutical Co., Ltd Japan (OPCJ) | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory University | Atlanta | Georgia | 30329 | United States |
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D001523 | Mental Disorders |
| D000341 | Affective Disorders, Psychotic |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000591922 | brexpiprazole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from Phase B baseline to Phase B Week 6 in Visual Analog Scale (VAS) | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) score | Week 6 |
| Clinical Global Impression - Improvement Scale (CGI-I) score at Phase B Week 6 | Week 6 |
| MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Phase B baseline to Phase B Week 6 | Week 6 |
| MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Phase B baseline to Phase B Week 6 | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Sheehan Disability Scale (SDS) 3-item mean score | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Anger Attacks Questionnaire (AAQ) score | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Symptoms of Depression Questionnaire (SDQ) | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Kellner Symptom Questionnaire (KSQ) | Week 6 |
| Change from Phase B baseline to Phase B Week 6 in Barratt Impulsiveness Scale 11 item (BIS-11) Total Score | Week 6 |